Business
Currency:CNY
2024/FY
Stock NameRevenueRatio
来自销售药品的收入215.2M83.34%
中国内地独家推广许可权收入30.53M11.82%
合同研发生产协议收入12.44M4.82%
提供合约服务的收入71K0.03%
Product
Currency:CNY
2024/FY
Stock NameRevenueRatio
来自销售药品的收入215.2M83.34%
中国内地独家推广许可权收入30.53M11.82%
合同研发生产协议收入12.44M4.82%
提供合约服务的收入71K0.03%
Region
Currency:CNY
2024/FY
Stock NameRevenueRatio
The mainland of China258.23M100.00%